The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
Open accessAbstract
BACKGROUND: The global emergence of carbapenem-resistant Enterobacteriaceae highlights the urgent need to reduce carbapenem dependence. The phase 3 RECAPTURE program compared the efficacy and safety of ceftazidime-avibactam and doripenem in patients with complicated urinary tract infection (cUTI), including acute pyelonephritis. METHODS: Hospitalized adults with suspected or microbiologically confirmed cUTI/acute pyelonephritis were randomized 1:1 to ceftazidime-avibactam 2000 mg/500 mg every 8 hours or doripenem 500 mg every 8 hours (doses adjusted for renal function), with possible oral antibiotic switch after ≥5 days (total treatment duration up to 10 days or 14 days for patients with bacteremia). RESULTS: Of 1033 randomized patients, 393 and 417 treated with ceftazidime-avibactam and doripenem, respectively, were eligible for the primary efficacy analyses; 19.6% had ceftazidime-nonsusceptible baseline pathogens. Noninferiority of ceftazidime-avibactam vs doripenem was demonstrated for the US Food and Drug Administration co-primary endpoints of (1) patient-reported symptomatic resolution at day 5: 276 of 393 (70.2%) vs 276 of 417 (66.2%) patients (difference, 4.0% [95% confidence interval {CI}, -2.39% to 10.42%]); and (2) combined symptomatic resolution/microbiological eradication at test of cure (TOC): 280 of 393 (71.2%) vs 269 of 417 (64.5%) patients (difference, 6.7% [95% CI, .30% to 13.12%]). Microbiological eradication at TOC (European Medicines Agency primary endpoint) occurred in 304 of 393 (77.4%) ceftazidime-avibactam vs 296 of 417 (71.0%) doripenem patients (difference, 6.4% [95% CI, .33% to 12.36%]), demonstrating superiority at the 5% significance level. Both treatments showed similar efficacy against ceftazidime-nonsusceptible pathogens. Ceftazidime-avibactam had a safety profile consistent with that of ceftazidime alone. CONCLUSIONS: Ceftazidime-avibactam was highly effective for the empiric treatment of cUTI (including acute pyelonephritis), and may offer an alternative to carbapenems in this setting. CLINICAL TRIALS REGISTRATION: NCT01595438; NCT01599806.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Performance standards for antimicrobial susceptibility testing
Ferraro, M. J. (2001) · Cited by 9,667
Urinary tract infections: epidemiology, mechanisms of infection and treatment options
Flores-Mireles, A. L., Walker, J. N., Caparon, M., & Hultgren, S. J. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3432 · Cited by 4,213
Interval estimation for the difference between independent proportions: comparison of eleven methods
Newcombe, R. G. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980430)17:8<873::aid-sim779>3.0.co;2-i · Cited by 1,851
Zimlichman, E., Henderson, D., Tamir, O., Franz, C., Song, P., Yamin, C. K., Keohane, C., Denham, C. R., & Bates, D. W. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.9763 · Cited by 1,847
The epidemiology of urinary tract infection
Foxman, B. (2010) · Nature Reviews Urology · doi:10.1038/nrurol.2010.190 · Cited by 1,771
Comparative analysis of two rates
Miettinen, O., & Nurminen, M. (1985) · Statistics in Medicine · doi:10.1002/sim.4780040211 · Cited by 1,110
Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe
Cantón, R., Akóva, M., Carmeli, Y., Giske, C. G., Glupczynski, Y., Gniadkowski, M., Livermore, D. M., Miriagou, V., Naas, T., Rossolini, G. M., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2012.03821.x · Cited by 883
Carmeli, Y., Armstrong, J., Laud, P. J., Newell, P., Stone, G., Wardman, A., & Gasink, L. B. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30004-4 · Cited by 417
Self-citationMazuski, J. E., Gasink, L. B., Armstrong, J., Broadhurst, H., Stone, G. G., Rank, D., Llorens, L., Newell, P., & Pachl, J. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw133 · Cited by 393
Self-citationThe emerging threat of multidrug-resistant Gram-negative bacteria in urology
Zowawi, H. M., Harris, P. N. A., Roberts, M. J., Tambyah, P. A., Schembri, M. A., Pezzani, M. D., Williamson, D. A., & Paterson, D. L. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.199 · Cited by 361
Zilberberg, M. D., Shorr, A. F., Micek, S. T., Vazquez-Guillamet, C., & Kollef, M. H. (2014) · Critical Care · doi:10.1186/preaccept-6556009101270526 · Cited by 340
Kanj, S. S., & Kanafani, Z. A. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0674 · Cited by 269
Lahiri, S. D., Mangani, S., Durand-Reville, T., Benvenuti, M., De Luca, F., Sanyal, G., & Docquier, J.-D. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02247-12 · Cited by 230
Johansen, T. E. B., Botto, H., Cek, M., Grabe, M., Tenke, P., Wagenlehner, F. M. E., & Naber, K. G. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.09.009 · Cited by 222
Self-citationVazquez, J. A., González Patzán, L. D., Stricklin, D., Duttaroy, D. D., Kreidly, Z., Lipka, J., & Sable, C. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.748653 · Cited by 219
Carbapenem-resistant Enterobacteriaceae: A menace to our most vulnerable patients
Perez, F., & Van Duin, D. (2013) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.80a.12182 · Cited by 184
Castanheira, M., Farrell, S. E., Krause, K. M., Jones, R. N., & Sader, H. S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01896-13 · Cited by 177
Samuelsen, O., Naseer, U., Tofteland, S., Skutlaberg, D. H., Onken, A., Hjetland, R., Sundsfjord, A., & Giske, C. G. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp018 · Cited by 171
Lagacé-Wiens, P., Walkty, A., & Karlowsky, J. (2014) · Core Evidence · doi:10.2147/ce.s40698 · Cited by 169
Levison, M. E., & Kaye, D. (2013) · Current Infectious Disease Reports · doi:10.1007/s11908-013-0315-7 · Cited by 156
Hsueh, P., Hoban, D. J., Carmeli, Y., Chen, S., Desikan, S., Alejandria, M., Ko, W., & Bình, T. Q. (2011) · Journal of Infection · doi:10.1016/j.jinf.2011.05.015 · Cited by 149
Raman, G., Avendano, E. E., Berger, S. E., & Menon, V. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-1123-5 · Cited by 137
Clayson, D. J., Wild, D. J., Doll, H., Keating, K. N., & Gondek, K. (2005) · British Journal of Urology · doi:10.1111/j.1464-410x.2005.05630.x · Cited by 115
Chen, Y., Ko, W., & Hsueh, P. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.778827 · Cited by 103
Elhanan, G., Sarhat, M., & Raz, R. (1997) · Journal of Infection · doi:10.1016/s0163-4453(97)93194-7 · Cited by 94
Golan, Y. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-1054-1 · Cited by 62
Nadkarni, A. S., Schliep, T., Khan, L., & Zeana, C. B. (2009) · American Journal of Infection Control · doi:10.1016/j.ajic.2007.10.013 · Cited by 54
MacVane, S. H., Crandon, J. L., Nichols, W. W., & Nicolau, D. P. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03267-14 · Cited by 46
Cited by
Tamma, P. D., Heil, E. L., Justo, J. A., Mathers, A. J., Satlin, M. J., & Bonomo, R. A. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae403 · Cited by 1,191
Paul, M., Carrara, E., Retamar, P., Tängdén, T., Bitterman, R., Bonomo, R. A., de Waele, J., Daikos, G. L., Akova, M., Harbarth, S., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.11.025 · Cited by 1,056
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad428 · Cited by 740
Rodríguez-Baño, J., Gutiérrez-Gutiérrez, B., Machuca, I., & Pascual, A. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00079-17 · Cited by 704
Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
Doi, Y. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz830 · Cited by 652
Metadata
- Authors
- Wagenlehner, F. M., Sobel, J. D., Newell, P., Armstrong, J., Huang, X., Stone, G. G., Yates, K., & Gasink, L. B.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-06-16
- Volume
- 63
- Issue
- 6
- Pages
- 754-762
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2437593726
- Cited by
- 362
- References
- 28
- FWCI
- 36.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.